SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical firm creating a platform round its newly found class of enzymes to focus on Parkinson’s illness and lots of different age-related and inflammatory problems, immediately introduced the formation of its Scientific Advisory Board (SAB). Trade drug discovery and growth veteran, James Summers, Ph.D., has been appointed chairperson of the SAB.
“As we embark on newly found science in growing old and irritation biology, we stay up for thought management and shut collaboration with the scientific leaders appointed to our SAB ,” mentioned Irene Griswold-Prenner, Ph.D., founder, chief government officer and chief scientific officer of Nitrome. “We’re thrilled that this esteemed group of scientists has agreed to help our imaginative and prescient of advancing Nitrome science to sufferers. We stay up for Jim’s management and steering as our SAB chair as we translate Nitrome science into essential therapeutics.”
Dr. Summers added, “Dr. Griswold-Prenner’s discovery of a completely new class of enzymes has the potential to rework the remedy of Parkinson’s illness and different age-related problems. I’m honored to be part of this modern scientific staff. I very a lot stay up for working with the opposite SAB members and the corporate’s very good analysis and growth staff to information Nitrome discoveries into medical growth.”
The SAB will probably be comprised of the next members:
SAB Chairparticular person – James Summers, Ph.D., former Vice President, Neuroscience Analysis, AbbVie
James B. Summers, Ph.D., has greater than three a long time of drug discovery and pharmaceutical analysis administration expertise spanning a number of therapeutic areas. Beneath his management at Abbott Laboratories and at AbbVie, groups have superior greater than 20 compounds into medical growth. He established new analysis websites in Cambridge, Massachusetts and Shanghai, China, was an architect of a number of methods that outlined the longer term path of world analysis organizations, and championed a number of profitable licensing offers, biotech collaborations and enterprise investments. Dr. Summers has held numerous senior R&D management positions the place he led efforts targeted on the invention of recent medicine for the remedy of Alzheimer’s and Parkinson’s ailments, ache, and psychiatric problems. Most lately, he was vp of neuroscience analysis at AbbVie. Dr. Summers additionally served as divisional vp, superior expertise with Abbott the place he was chargeable for a company engaged in a broad vary of applied sciences and core companies that enabled and accelerated drug discovery analysis throughout all of Abbott’s therapeutic areas and websites. Dr. Summers holds a BS, summa cum laude, in chemistry from Denison College and a Ph.D. in natural chemistry from Harvard College.
Harry Ischiropoulos, Ph.D., Kids’s Hospital of Philadelphia
Harry Ischiropoulos, Ph.D., is the Gisela and Dennis Alter analysis professor of Pediatrics and Methods Pharmacology and Translational Therapeutics on the Kids’s Hospital of Philadelphia Analysis Institute and the Perelman Faculty of Medication on the College of Pennsylvania. His laboratory investigates the organic chemistry and signaling pathways of nitric oxide within the cardiovascular and neuronal programs utilizing mass spectroscopy-based applied sciences. Dr. Ischiropoulos has authored 195 publications and is the recipient of a number of skilled awards together with an Established Investigator award from the American Coronary heart Affiliation. He served on a number of NIH assessment panels and advisory committees. He was the president for the Society for Free Radical Biology and Medication and served on the board of administrators for the Federation of American Societies for Experimental Biology. He was an editor for the journal Free Radical Biology and Medication and chaired the Gordon Analysis Conferences on Oxygen Radicals (2014) and on Nitric Oxide (2015). Dr. Ischiropoulos obtained a BS in chemistry from Wagner School, an MS in pathology and a Ph.D. in experimental pathology from New York Medical School.
Regis B. Kelly, Ph.D., Govt Director QB3
Regis B. Kelly, Ph.D., is the chief director of QB3, one of many 4 Governor Grey Davis Institutes for Science and Innovation. As government director, Dr. Kelly helped launch two QB3-associated corporations, QB3@953 now MBC Biolabs, a life sciences startup incubator, and Mission Bay Capital, a enterprise fund. Because of his experiences, Dr. Kelly was appointed as senior advisor on innovation and entrepreneurship to the president of the College of California, Janet Napolitano. Previous to becoming a member of QB3 in 2004, Dr. Kelly served as government vice-chancellor at UCSF and chairman of the division of biochemistry and biophysics. Dr. Kelly obtained an undergraduate diploma in physics from the College of Edinburgh in Scotland and a Ph.D. in biophysics from the California Institute of Know-how. Following a post-doctoral fellowship at Stanford, Dr. Kelly was an teacher within the division of neurobiology at Harvard.
Stevan W Djuric, Ph.D., former Head of International Medicinal Chemistry, AbbVie
Stevan W Djuric, Ph.D., was, till retirement in February 2019, head of the worldwide AbbVie medicinal chemistry management staff at AbbVie and Vice President of the Discovery Chemistry and Know-how group. The expertise group’s efforts have been targeted on initiatives within the areas of excessive throughput synthesis and purification, hit-to-lead chemistry, chemical biology and new MS-based analytical applied sciences. In 2015 he was named a Distinguished Analysis Fellow. Throughout his tenure at Abbott and AbbVie Laboratories, Dr. Djuric was a venture chief for teams within the immunoscience, metabolic illness, and anti-infective areas. A number of of those applications superior compounds into medical growth and to the market together with Abbott’s proprietary rapamycin analog, Zotarolimus, presently licensed to Medtronics to be used on their vascular stents, marketed in the USA and Europe. Dr. Djuric has over 180 scientific publications, displays and patents/purposes pending. He has additionally given over 40 invited lectures at universities and nationwide conferences. He’s a member of a number of Editorial Advisory Boards together with the Journal of Medicinal Chemistry and is an Affiliate Editor of ACS Medicinal Chemistry Letters. As well as, he holds an Adjunct Professorship within the Division of Medicinal Chemistry on the College of Kansas and one at Excessive Level College in North Carolina.
Zach W. Corridor, Ph.D., Neurobiologist, former President of CIRM
Zach W. Corridor, Ph.D., is a retired neuroscientist whose laboratory studied the molecular construction and growth of the neuromuscular junction. He obtained his Ph.D. with Ed Kravitz at Harvard College in 1966. Following two years of post-doctoral work within the Division of Biochemistry at Stanford, Corridor returned to Harvard to hitch the brand new Division of Neurobiology as an Assistant Professor. In 1976 he moved to UCSF the place he began the Neuroscience Graduate Program. From 1994-97 he was director of the Nationwide Institute of Neurological Problems and Stroke earlier than returning to UCSF as Govt Vice Chancellor, with accountability for creating the campus at Mission Bay. He then held a collection of administrative positions, together with the CEO of EnVivo Prescribed drugs and later Affiliate Dean for Analysis on the Keck Faculty of Medication on the College of Southern California. His final place was as the primary president of the California Institute of Regenerative Medication, a brand new state company to fund stem cell analysis in California. Corridor was one of many founding editors of Neuron, and is the creator and editor of a textbook, An Introduction to Molecular Neurobiology. He has obtained quite a lot of honors, together with the Purkynje Medal from the Czech Academy of Sciences. Corridor, who now lives in Wilson, WY, presently serves as an advisor and board member for Goal ALS, a non-profit group dedicated to dashing the event of therapies for ALS by selling collaboration between trade and academia.
Kalpana Service provider, Ph.D., Neuroscientist, former Eli Lilly, Pharmacia
Kalpana Service provider, Ph.D., an knowledgeable in neurobiology of persistent neurodegenerative and psychiatric problems, has practically 25 years of expertise in drug discovery and growth, with a particular emphasis on translational approaches. She retired from Eli Lilly in 2014 the place she was the chief scientific officer for tailor-made therapeutics-neuroscience, the place her staff was accountable for personalised therapies and related biomarkers for the neuroscience portfolio. Dr. Service provider joined Eli Lilly in 2003 after contributing to neuroscience drug discovery at Pharmacia Corp. for over 10 years. Since 2014, she has held chief government/scientific officer roles at Chaperone Therapeutics and Vincere Biosciences. She serves as an advisor to the Michael J Fox Basis for Parkinson’s analysis, a number of NIH working teams and quite a lot of start-up pharmaceutical corporations. She is an Adjunct Professor of Neurology at Northwestern College. Dr. Service provider obtained her Ph.D. in neuropharmacology from College of Utah in 1989. Following a postdoctoral fellowship at College of Washington, she remained on the institute as assistant professor of psychiatry, later transitioning to the pharmaceutical trade.
About Nitrome Biosciences
Nitrome Biosciences is a platform firm creating medicine towards a newly recognized class of enzymes which play a dangerous function in a wide range of age and irritation dependent ailments. The therapies that Nitrome is creating will goal these enzymes and probably assist sluggish or halt the development of ailments together with Parkinson’s, Nitrome’s lead indication. The corporate additionally goals to broaden its proprietary platform to incorporate different ailments, akin to different neurodegenerative ailments, macular degeneration, coronary heart illness and most cancers. Nitrome has been well known and has received a number of awards together with the celebrated Goal Development grant from The Michael J. Fox Basis for Parkinson’s Analysis (MJFF). For extra info, please go to the corporate’s web site at www.nitromebiosciences.com.
Investor Relations Contact:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Media Contact:
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
